14-day Premium Trial Subscription Try For FreeGet Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of HROW
Powered by GPT-4
Stock Analysis
Risk Assessment
Trading Strategy

Green day on Friday for Imprimis Pharmaceuticals stock after gaining 1.5560165975104%
(Updated on Dec 08, 2023)

Sell candidate since Nov 01, 2023 Loss -27.21% PDF
The Imprimis Pharmaceuticals stock price gained 1.5560165975104% on the last trading day (Friday, 8th Dec 2023), rising from $9.64 to $9.79. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 2.81% from a day low at $9.62 to a day high of $9.89. The price has risen in 6 of the last 10 days and is up by 4.37% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 244 thousand more shares were traded than the day before. In total, 477 thousand shares were bought and sold for approximately $4.67 million.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -36.67% during the next 3 months and, with a 90% probability hold a price between $3.99 and $7.73 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

HROW Signals & Forecast

A buy signal was issued from a pivot bottom point on Wednesday, November 15, 2023, and so far it has risen 20.86%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Imprimis Pharmaceuticals stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $11.34. On a fall, the stock will find some support from the short-term average at $9.52. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Maximize Your Market Edge: Go Premium for In-Depth AI-Powered Stock Research and Exclusive Lists! 🚀

Support, Risk & Stop-loss for Imprimis Pharmaceuticals stock

On the downside, the stock finds support just below today's level from accumulated volume at $8.60 and $8.21. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Imprimis Pharmaceuticals finds support just below today's level at $8.60. If this is broken, then the next support from accumulated volume will be at $8.21 and $8.10.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.270 between high and low, or 2.81%. For the last week, the stock has had daily average volatility of 3.53%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (HROW) For The Upcoming Trading Day Of Monday 11th

For the upcoming trading day on Monday, 11th we expect Imprimis Pharmaceuticals to open at $9.77, and during the day (based on 14 day Average True Range), to move between $9.19 and $10.39, which gives a possible trading interval of +/-$0.596 (+/-6.09%) up or down from last closing price. If Imprimis Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 12.18% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $8.60, some $1.19 (12.16%) from the current price of $9.79, our system finds the risk reward attractive.

Is Imprimis Pharmaceuticals stock A Buy?

Imprimis Pharmaceuticals holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.358 Open Broker Account

Sell Candidate Unchanged

Predicted Opening Price for Imprimis Pharmaceuticals of Monday, December 11, 2023

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Fair opening price December 11, 2023 Current price
$9.77 $9.79 (Overvalued)

Remember To Visit Our YouTube Channel

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 10.04 2.52 %
R2 9.93 1.47 %
R1 9.87 0.82 %
Current price: 9.79
Support S1 9.66 -1.29 %
S2 9.60 -1.94 %
S3 9.50 -3.00 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 0 .
R1 0 .
Current price 9.79
Support S1 8.60 -12.16%
S2 8.21 -16.14%
S3 8.10 -17.26%
What is the symbol for Imprimis Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Imprimis Pharmaceuticals is HROW and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Imprimis Pharmaceuticals Stock?
Imprimis Pharmaceuticals holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy Imprimis Pharmaceuticals Stock?
Imprimis Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Imprimis Pharmaceuticals Stock.

What's the current price of Imprimis Pharmaceuticals Stock?
As of the end of day on the 2023-12-08, the price of an Imprimis Pharmaceuticals (HROW) share was $9.79.

What is the 52-week high and low for Imprimis Pharmaceuticals Stock?
The 52-week high for Imprimis Pharmaceuticals Stock is $28.25 and the 52-week low is $7.60.

What is the market capitalization of Imprimis Pharmaceuticals Stock?
As of the 2023-12-08, the market capitalization of Imprimis Pharmaceuticals is 337.832M.

When is the next earnings date for Imprimis Pharmaceuticals?
The upcoming earnings date for Imprimis Pharmaceuticals is 2024-03-28 00:00:00.

Click to get the best stock tips daily for free!

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharma... HROW Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE